Seres Therapeutics (MCRB) Expected to Announce Earnings on Thursday

Seres Therapeutics (NASDAQ:MCRB) will likely be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect Seres Therapeutics to post earnings of ($0.17) per share for the quarter.

Seres Therapeutics Stock Up 14.1 %

NASDAQ MCRB opened at $0.76 on Thursday. The stock has a market cap of $130.60 million, a P/E ratio of -3.33 and a beta of 2.11. The company’s 50-day simple moving average is $0.82 and its 200 day simple moving average is $0.84. Seres Therapeutics has a twelve month low of $0.54 and a twelve month high of $1.53.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on MCRB shares. Chardan Capital reissued a “buy” rating and issued a $1.25 target price on shares of Seres Therapeutics in a research note on Wednesday, November 13th. StockNews.com cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, February 25th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $10.00 target price on shares of Seres Therapeutics in a research note on Thursday, November 14th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $5.08.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.